Compare iShares MSCI Canada (TSX) (EWC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Incyte Corporation — how do they compare? iShares MSCI Canada (TSX) trades at $61.51, while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: iShares MSCI Canada (TSX) is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| EWC | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.51 | $129.93 |
52-Week Low | $47.00 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
